Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
<p>Abstract</p> <p>Background</p> <p>The use of imatinib mesylate is associated with a progression free survival of 41 months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatin...
Main Authors: | Seidel Christoph, Fenner Martin, Länger Florian, Bantel Heike, Ganser Arnold, Grünwald Viktor |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2407/12/186 |
Similar Items
-
Appropriate durations of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumor (GIST) the better choice, for the year 2010
by: Lucia Tozzi
Published: (2015-10-01) -
Imatinib as adjuvant therapy for high risk GIST: a case report
by: Patrizia Lista, et al.
Published: (2015-10-01) -
Imatinib dose optimisation following the disease progression in a patient with metastatic GIST
by: Mariangela Parodi, et al.
Published: (2015-10-01) -
Crossing-over to imatinib 800 mg in a patient with GIST, after progression with standard
dosage: a case report
by: Giuseppe Naso, et al.
Published: (2015-10-01) -
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
by: Adnan Asif Parvez Ghias, et al.
Published: (2018-03-01)